The Emirates Drug Establishment (EDE) has approved Baxfendy to treat hypertension in patients who are unable to adequately control blood pressure levels through traditional medications.
Baxfendy contains the active substance baxdrostat, developed by AstraZeneca, which lowers blood pressure by inhibiting an enzyme responsible for aldosterone production. The drug is available in 1 mg and 2 mg doses.
“Approving this treatment is yet another significant step towards enabling advanced medical solutions that precisely target disease pathways, particularly in cases that do not respond to traditional options, while ensuring uninterrupted access for patients,” said Dr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment.
Hypertension is one of the most pressing health challenges in the UAE, with estimates indicating that approximately one in three adults is affected, making it among the most prevalent non-communicable diseases in the country.
Despite the availability of multiple treatment options, control rates remain below optimal levels, making the addition of the new medication a closer step to supporting the disease.
Fujairah says pipeline work triggered fire in petroleum industries area
Yas Island announced as location for Sphere Abu Dhabi project
Warning issued on dangers of sudden road stops after 1 dead, 19 injured
UAE says reports of Israeli PM Netanyahu's visit 'entirely unfounded'
